aidot

[View original text]

On 28th of November, Buzzpole, which has developed Cerviray A.I., an artificial intelligence (AI)-based cervical cancer screening service, announced that it had completed the Ministry of Food and Drug Safety approval for a special camera for cervical imaging and started mass production and started preparations for export in earnest.

According to Buzzpole, Cerviray A.I. has advanced AI engine performance through joint research with the Korea University Anam Hospital Industry-University Cooperation Foundation and professors of obstetrics and gynecology for about two years.

Previously, last October, it was the only Korean AI medical ICT company to participate in the NTTDATA regional qualifier held in Shenzhen, China, and received good reviews in terms 

of service model and marketability.

As Buzzpole is already in the process of signing contracts with companies that have received letters of intent from Southeast Asia, including China, it is expected to achieve tangible 

export results for the first time as a domestic company early next year.

Cerviray A.I., which applied Buzzpole's own deep learning algorithm, has recently been certified with a sensitivity of 87% and specificity of 90% through an internationally recognized 

software test center.

Dr. Dong-hyun Lee of the Buzzpole Research Institute explained, "The sensitivity can be raised to 99%, but this only blindly emphasizes the sensitivity without considering the 

specificity."

He emphasized, “For example, if it is even a little strange, it is natural that the technology that identifies a cancer patient is ignored in the actual field, and in the field of medical image reading, AI engine performance must balance both sensitivity and specificity.”

Seong-won Choi, director of Buzzpole, who has been strategically pursuing business in China and Southeast Asia, confidently said, “We are planning to start full-scale mass 

production early next year, and based on our export performance through this, we will be recognized for the global competitiveness of Buzzpole AI service.”

In particular, Director Choi said and ponted, “No matter how many papers there are and how good the technology is, there is no market in Korea because various regulations and 

medical insurance fees do not apply. In addition, there is already a company that is more advanced in related products overseas, so if the product is not introduced, everything will end 

in empty talk.”

At the same time, he emphasized “When some domestic AI medical ICT companies are blindly going all-in on the technology special listing system, which is currently much talked 

about without worrying about specific business, Buzzpole has been running for overseas pioneering even in a difficult environment, and now it is about to produce tangible results.”

|Medical Times=Reporter Hee-seok Jeong|